REFERENCES
1. Hargrave, D. R.; Bouffet, E.; Tabori, U.; Broniscer, A.; Cohen, K. J.; Hansford, J. R.; Geoerger, B.; Hingorani, P.; Dunkel, I. J.; Russo, M. W.; Tseng, L.; Dasgupta, K.; Gasal, E.; Whitlock, J. A.; Kieran, M. W., Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clinical Cancer Research 2019,25 (24), 7303-7311.
2. TAFINLAR (dabrafenib): Highlights of prescribing information. U.S. Food and Drug Administration: 2013.
3. MEKINIST (trametinib): Highlights of prescribing information. U.S. Food and Drug Administration: 2013.
4. Kieran, M. W.; Geoerger, B.; Dunkel, I. J.; Broniscer, A.; Hargrave, D.; Hingorani, P.; Aerts, I.; Bertozzi, A. I.; Cohen, K. J.; Hummel, T. R.; Shen, V.; Bouffet, E.; Pratilas, C. A.; Pearson, A. D. J.; Tseng, L.; Nebot, N.; Green, S.; Russo, M. W.; Whitlock, J. A., A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res 2019, 25 (24), 7294-7302.
5. Wang, J. R.; Zafereo, M. E.; Dadu, R.; Ferrarotto, R.; Busaidy, N. L.; Lu, C.; Ahmed, S.; Gule-Monroe, M. K.; Williams, M. D.; Sturgis, E. M.; Goepfert, R. P.; Gross, N. D.; Lai, S. Y.; Gunn, G. B.; Phan, J.; Rosenthal, D. I.; Fuller, C. D.; Morrison, W. H.; Iyer, P.; Cabanillas, M. E., Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Thyroid 2019, 29 (8), 1036-1043.
Figure 1 A Axial T2 image prior to resection and treatment initiation demonstrates increased T2 signal and mild expansion of the cervical medullary junction worrisome for infiltrative tumor. B Axial T2 image 3 months after liquid suspension initiation shows no tumor progression with some improvement in treatment response.